First, the antitumor role of DNASE1L3 in CRC development uncovered in our study has implications in inflammatory bowel disease (IBD) or colon cancer treatment in the clinic; the antitumor role of DNASE1L3 suggests that DNASE1L3 protein or a DNASE1L3-carrying vector may be considered as a potential therapeutic tool to help colon recovery or improve colon cancer therapy. This evidence concerns the gene DNASE1L3 and malignant colon neoplasm.